April 3, 2025 12:16 PM EDTUpdated April 4, 08:41 AM

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data

Ayisha Sharma

News Reporter

Roche on Thursday shared early positive results for its Alzheimer’s candidate trontinemab, the latest round of data in its second attempt to develop a drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data

Ayisha Sharma

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Roche plans Phase 3 for its lat­est Alzheimer’s drug at­tempt af­ter un­veil­ing more ear­ly da­ta

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data